ABSTRACT
INTRODUCTION
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β (TGF-β) superfamily that function as extracellular signaling proteins (Urist, 1965; Wozney, 1992; Reddi, 2001) . BMPs are pleiotropic whole-body morphogens involved in proliferation, differentiation, and maintenance of diverse tissue types (ten Dijke et al., 1994; Yamashita et al., 1995) . BMP signaling is primarily mediated though binding to a heterotetrameric complex of cognate type I and type II receptors (BMPRs).
Upon ligand binding, the serine/threonine kinase on the Type II receptors phosphorylates the Type I receptors, triggering intracellular Smad signal transduction cascades.
Phosphorylation of the BMP-specific intracellular Smads (Smad-1, -5, and -8) allows them to bind the partnering co-Smad, Smad4 (Yamashita et al., 1995; Kawabata et al., 1998; Miyazono et al., 2000; Miyazono et al., 2001; Moustakas et al., 2001; Chen et al., 2004) . This complex of Smads and other DNA binding proteins undergoes nuclear translocation and triggers transcriptional activation of target genes, including cell cycle regulators or apoptosis mediators such as p21/Cip1/Waf1, bax, and p53 (Chen et al., 2002; Pouliot and Labrie, 2002; Fukuda et al., 2006) .
Regulation of BMP signaling is accomplished in a tissue-specific manner via BMP antagonists (Yanagita, 2005; . Classical BMP antagonists bind BMPs in the extracellular space, preventing the association of BMPs with their receptors. BMP antagonists may also prevent the activity of BMPs by fostering their retention in the ER (Guidato and Itasaki, 2007) . BMP antagonists have been postulated to act as the key 'on/off' switches that spatially and temporally regulate local BMP activity. Thus, BMP antagonists may represent local targets to control specific tumors.
In addition to their effects on BMP pathways, BMP antagonists have also been reported to impinge on Wnt signaling, For example, sclerostin exerts its inhibitory effects on bone formation in mice primarily through inhibition of Wnt signaling (van Bezooijen et al., 2007) ; in Xenopus, the BMP antagonist Wise inhibits or stimulates Wnt signaling in a manner dependent on context (Itasaki et al., 2003) and cellular localization (Guidato and Itasaki, 2007) .
Several genes have been implicated in the development of renal clear cell carcinoma. These include VHL, an ubiquitin ligase and tumor suppressor, as well as cMet and BHD (Linehan et al., 2005; Brugarolas, 2007) . To identify novel genes whose expression is altered in renal cancer, we probed arrays of secreted and cell surface cDNAs with cDNA libraries prepared from tumor tissue and matched normal tissue from 20 kidney cancer patients. This screen identified SOSTDC1, a BMP antagonist, as a candidate gene with reduced expression in renal cancer.
SOSTDC1 is orthologous to a recently characterized murine antagonist of BMPs-2, -4, and -7 termed ectodin/USAG-1 (Mus musculus) (Yanagita et al., 2004) . In other species, this protein is known as USAG-1 (Rattus norvegius) (Yanagita et al., 2004) , ectodin (Mus musculus) (Laurikkala et al., 2003; Kassai et al., 2005) , and wise (Xenopus laevis) (Itasaki et al., 2003) . Recent mouse knock-outs of ectodin/USAG-1 have shown that this molecule is important in tooth formation and modulation of the renoprotective effects of BMP-7 (Kassai et al., 2005; Yanagita et al., 2006) . The human protein is 98% identical to the rodent protein, and like most members of the BMP and BMP antagonist families, is predicted to contain a C-terminal cystine-knot motif (Avsian-Kretchmer and Hsueh, 2004) . However, the role of SOSTDC1 in human tissues or human cancers has not been reported.
In this report, we demonstrate that SOSTDC1 is highly expressed in cells of the normal human kidney, but is significantly decreased in clear cell renal carcinoma.
MATERIALS & METHODS

Recombinant proteins and reagents
Recombinant human BMP-7 (rhBMP-7), noggin-Fc chimera, recombinant mouse Wnt-3a (rmWnt-3a), and DKK1 were purchased from R & D Systems (Minneapolis, MN). Mammalian expression vectors encoding the open reading frame (ORF) for BMP-7 (pReceiver-M2-BMP7), dickkopf-1 (DKK1; pReceiver-M2-DKK1), noggin (pReceiver-M02-noggin), and Wnt-3a (pReceiver-M02-Wnt3a) were purchased from GeneCopoeia, Inc. (Germantown, MD). The TCF/LEF luciferase reporter construct Super 8X TOPFlash and the corresponding mutant control Super 8X FOPFlash vectors were obtained from the Addgene Repository (Cambridge, MA. Plasmids deposited by Dr. Randall Moon (Veeman et al., 2003) .
The following commercial antibodies were obtained: anti-phospho-Smad-1,-5,-8 (Cell Signaling Technologies, Danvers, MA), anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Research Diagnostics International, Flanders, NJ) , and mouse monoclonal anti-FLAG (Sigma Aldrich, St. Louis, MO).
Production of anti-hSOSTDC1 antisera
Production and affinity purification of an anti-SOSTDC1 peptide polyclonal rabbit anti-sera directed against the 18 C-terminal amino acids of the SOSTDC1 sequence was performed by Quality Control Biochemicals Custom Services (Hopkinton, MA).
Cells and culture conditions
Human embryonic kidney cells, HEK293, were maintained in Dulbecco's 
Mammalian Vector Construction and preparation of recombinant, human
SOSTDC1 (rhSOSTDC1)
The open reading frame encoding the SOSTDC1 protein (NCBI: NM_015464) without the final stop codon was amplified from cDNA by polymerase chain reaction (PCR) and cloned into the BamH1/Asp718 restriction sites of the pFLAG-CMV5a vector (Invitrogen). The resulting recombinant human SOSTDC1 (rhSOSTDC1) has the FLAG (DYKDDDDK) epitope added to its C-terminus.
HEK293 cells were transiently transfected with the pFLAG-CMV5A SOSTDC1 vector using LipofectAMINE™ reagent (Invitrogen). Conditioned media was harvested after 2 days and purified using an anti-FLAG M2 affinity column (Sigma, St. Louis, MO).
Tissue Samples and Immunohistochemistry
All tissue samples were used with approval from the Institutional Review Board at Wake Forest University. Paraffin blocks from the pathology archives were sectioned at 5 micron intervals. After heat-induced antigen retrieval with Antigen Unmasking Solution (AUS, Vector Labs, Burlingame, CA), slides were stained with anti-SOSTDC1 polyclonal sera followed by affinity-purified goat anti-rabbit-IgG-HRP (Jackson ImmunoResearch) and diaminobenzidine (DAB) HRP substrate. The slides were counterstained with hematoxylin, viewed under brightfield conditions, and photographed at the same magnification.
Intracellular SOSTDC1 Relative Quantification
SOSTDC1 staining was quantified in Image J (NIH freeware (Rasband, 1997 (Rasband, -2007 as mean pixel intensity. Brightfield digital images of the peroxidase-stained tissues were collected at equal exposure conditions. To avoid bias of cell selection, an identical grid consisting of 9 equal squares was superimposed over every image digitally.
Only tumor cells crossing predetermined lines of the grid were included in analysis.
Analysis in Image J was completed via the "measure line" function as follows: a 5 pixel straight line selection was drawn in the perinuclear region of each candidate cell. Then, the "Measure" command was chosen from the Analyze menu. The mean pixel intensity value was averaged for 30 separate cells and reported as a percentage of maximal density.
Mix pixel intensity was also quantified using Adobe Photoshop (Lehr et al., 1997) , which gave virtually identical results.
Statistical Analysis
Statistical analysis was performed by the Biostatistics core of the Comprehensive Cancer Center of Wake Forest University. A one-way ANOVA was fit to compare the mean percent maximal density of the five groups. Pair wise comparisons were then performed between groups using a conservative p-value of 0.005 for significance (using a Bonferroni adjustment to allow for all 10 pair wise comparisons between groups to be made). Standard deviations for the outcome were compared across the five groups to assure that they were comparable.
cDNA microarray and RNA dot blot
Microarray analyses were performed on tissues from matched normal and tumor tissues from 20 kidney cancer patients and cDNAs from other normal and tumor tissue types. Labeled SOSTDC1 probes were hybridized to the array and resulting signals were scanned and quantified. To independently verify these results, the BD Clontech™ Cancer Profiling Array I, also having 20 matched normal and tumor kidney tissues, was probed with radiolabeled SOSTDC1. The majority of these tissues (~70%) are from patients with renal cell carcinoma, clear type.
rhSOSTDC1 transient transfection and immunofluorescence
pFLAG-CMV5a-SOSTDC1 was transiently transfected into HEK293 cells via LipofectAMINE™ reagent. Twenty-four hours after transfection, cells were washed once in room temperature PBS, and then fixed in 100% methanol at 4°C for 15 minutes.
Cells were labeled with anti-FLAG mouse monoclonal antibody (Sigma Aldrich) conjugated to rhodamine. Nuclei were stained with 4',6-Diamidino-2-phenylindole (DAPI, CalBiochem, EMD Biosciences, Inc., San Diego, CA) and cells were visualized through fluorescent microscopy.
Stimulation of phosphorylated Smad (p-Smad) production with BMP-7 and p-Smad immunoblot
Renal cancer cells were plated in phenol red-free McCoy's 5A with 5% FBS and 1% penicillin/streptomycin and allowed to attach overnight. Media was replaced with phenol-red free McCoy's 5A (Promocell GmBH, Heidelberg, Germany) containing 0.5% FBS and 1% penicillin/streptomycin with additions of rhBMP-7 (40 ng/mL), rhnoggin-Fc chimera (150 ng/mL) and/or rhSOSTDC1 (150 ng/mL). Cells were placed at 37°C for either 1 or 3 hours. At harvest, cells were washed with PBS, and 150 uL of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer added (0.5M Tris pH 6.8, 20% glycerol, 10% SDS, and 5% beta-mercaptoethanol). Lysates were electrophoresed on 10% SDS-PAGE gels, transferred to nitrocellulose, and p-Smad detected by Western blot analysis according to the instructions provided by the antibody supplier. p-Smad-1,-5,-8 was visualized with PicoWest chemiluminescent substrate (Pierce Biotechnology, Rockford, IL). GAPDH was used as a loading control.
Wnt signaling luciferase assay
Transfections were performed using Fugene6 (Roche Applied Science, Effect of SOSTDC1, noggin, and DKK1 on proliferation 50,000 cells of the 769-P cell line were plated per well of a 24 well plate. Cells were transfected with 0.4 μg either pFLAG-CMV5a empty vector control, pFLAGCMV5a-SOSTDC1, pReceiver-M02-Noggin, or pReceiver-M02-DKK1 with LipofectAMINE™ 2000 as described above. Twenty-four hours after transfection, FBS was added to the transfected cell cultures to a final concentration of 5%. Cells were allowed to recover from transfection for an additional 2 hours before trypsinization and reseeding at 5,000 cells per well in an E-plate for use on the ACEA RT-CES® system (ACEA Biosciences, Inc., San Diego, CA). This system allows real-time monitoring of cultures grown in a 96-well plate format. Each type of transfected cell was replated in its own conditioned media.
RESULTS
Downregulation of SOSTDC1 in renal tumors.
To identify novel genes whose expression is altered in cancer, we probed cDNA Of note, these matched samples were from a different set of kidney cancer patients than the 20 patients included in the microarray analysis. These results suggest that SOSTDC1 mRNA is downregulated in a majority of kidney cancers.
Expression of SOSTDC1 within the normal kidney and in kidney cancer.
To test whether expression of the SOSTDC1 protein was similarly affected, we prepared an anti-SOSTDC1 antibody and performed immunohistochemical analyses. We first evaluated the distribution of SOSTDC1 protein within the normal human kidney. (Table 1) . These results are consistent with the strong distal tubule expression observed for USAG-1, the murine homolog of SOSTDC1 (Yanagita et al., 2004) .
We then assessed the expression of SOSTDC1 in a variety of kidney tumor types.
Over 75% of kidney tumors are of the clear cell type. Papillary and chromophobe types are also seen. These represent approximately 15 and 5% of all kidney cancers, respectively, and have a more favorable prognosis than clear cell (Iliopoulos, 2006) . We investigated SOSTDC1 protein expression in these kidney tumor types and compared them to normal controls. In addition, we examined expression of SOSTDC1 in transitional cell carcinoma of the bladder. Representative images are shown in Figure 2 , and results are quantified in Figure 3 .
As seen in Figure 
SOSTDC1 is secreted and antagonizes signaling of BMP-7 in kidney cancer cells
We next assessed functional consequences of SOSTDC1 expression. As classic BMP antagonists function extracellularly, we first tested whether the localization of 
SOSTDC1 suppresses Wnt signaling in kidney cells
Since Wise, an ortholog of SOSTDC1, can both stimulate and inhibit the Wnt pathway (Itasaki et al., 2003) , we asked whether SOSTDC1 would affect Wnt signaling in human kidney cells. Cells were transfected with TOPFlash, a construct containing 8 TCF/LEF transcription factor binding sites upstream of the luciferase gene. Cells were co-transfected with Wnt-3a (to activate the classical Wnt/β-catenin/TCF signaling pathway) with and without co-transfection with SOSTDC1 expression vector. Cotransfection with DKK1, a known Wnt inhibitor, was used as a control. As seen in Figure 6 , Wnt-3a increased expression of the TOPFlash luciferase, and this response was blocked by DKK1. SOSTDC1 inhibited Wnt signaling to an extent comparable to DKK1. Thus, SOSTDC1 suppresses Wnt-3a signaling as well as BMP signaling in human kidney cells.
SOSTDC1 suppresses proliferation of RCC-clear cell cultures
Clear cell tumors are the most prevalent histopathologic type of kidney cancer.
Because these tumors showed the greatest change in SOSTDC1 protein expression inhibitor of the BMP pathway, or a vector encoding DKK1, an inhibitor of the Wnt pathway, and effects on proliferation measured. As seen in Figure 7 , inhibition of either of these pathways also inhibited proliferation, although the effect was more modest than that seen with SOSTDC1.
DISCUSSION
Differential expression of genes in normal and cancer tissue has been used to study processes involved in malignant change, to identify new tumor markers, and to identify new targets in tumor therapy. Motivated by these goals, we sought to identify secretory or cell surface proteins altered in kidney cancer. Several genes have been implicated in the development of renal clear cell carcinoma, including VHL, a ubiquitin ligase and tumor suppressor, as well as c-Met, BHD and sFRP1 (Linehan et al., 2005; Brugarolas, 2007) ; (Gumz et al., 2007) ; however current molecular understanding of the disease is incomplete. To identify novel genes whose expression is altered in renal cancer, we probed arrays of secreted and cell surface cDNAs with cDNA libraries prepared from tumor tissue and matched normal tissue from 20 kidney cancer patients.
This screen identified SOSTDC1, a BMP antagonist, as a candidate gene with reduced expression in renal cancer.
Studies have previously linked BMPs, the target of BMP antagonists, as well as BMP receptors, to cancer. For example, aberrant BMP or BMPR expression has been noted in cancers, including osteosarcomas, breast, kidney, colon, prostate (Miyazaki et al., 2004; Hsu et al., 2005; Alarmo et al., 2006) . Smad4, the main intracellular target of both BMP and TGF-β signaling, is a known tumor suppressor in pancreatic and intestinal cancer (Alberici et al., 2006) .
SOSTDC1 is a BMP antagonist, as evidenced both by its sequence (Vitt et al., 2001; Avsian-Kretchmer and Hsueh, 2004) and function ( Figure 5 ). Although BMP antagonists have not been previously implicated in kidney cancer, they have been implicated in malignant processes in other tissue types. For example, noggin (a BMP antagonist) suppresses growth of implanted prostate cancer cells (Feeley et al., 2006) . DAN, another BMP antagonist discovered in v-mos transformed cells, inhibits neoplastic transformation (Chen et al., 2002) . However, the activities of BMP antagonists are complex and may vary. For example the BMP antagonist gremlin 1 is expressed by stromal cells associated with esophageal, pancreatic and other cancers (not including the kidney), and may promote tumor cell proliferation (Sneddon et al., 2006) . Our data demonstrate that in renal clear cell cancer, decreases in SOSTDC1 mRNA and protein are associated with malignant change. These data are the first link between the BMP antagonist SOSTDC1 and the process of carcinogenesis.
A number of intersections between BMP signaling and regulatory pathways important in carcinogenesis have been recently identified. These include such key cancer pathways as Wnt/β-catenin, PI3-K/PTEN, and MAPK/ERK (Aubin et al., 2004; He et al., 2004; Moustakas and Heldin, 2005; Pardali et al., 2005) . Further, BMP signaling directly impinges on the cell cycle regulatory proteins p21 and Rb: BMP signaling regulates p21/Cip1/Waf1 expression in prostate cancer (Haudenschild et al., 2004) , thyroid carcinomas (Franzen and Heldin, 2001) , and inhibits phosphorylation of Rb protein in breast cancer (Ghosh-Choudhury et al., 2000) .
We found that in human kidney cells, SOSTDC1 inhibits both BMP-7 ( Figure   5 ,6) and Wnt-3a (Figure 6 ) signaling. Similarly, previous reports have indicated that orthologs of SOSTDC1 can affect both BMP and Wnt pathways in complex ways that are dependent on context and cellular localization. USAG-1, the murine ortholog of SOSTDC1, binds to BMPs-2, -4 and -7 and antagonizes BMP activity in Xenopus embryos (Yanagita et al., 2004) . Wise, another ortholog of SOSTDC1 identified in chick and Xenopus, can both activate and antagonize Wnt signaling during Xenopus development (Itasaki et al., 2003; Guidato and Itasaki, 2007) .
Recent work has directly implicated the Wnt pathway in kidney cancer. WTX, a negative regulator of Wnt signaling, was identified as a new tumor suppressor in Wilms tumor, a pediatric form of kidney cancer (Major et al., 2007) . In a separate study using genomic profiling of adult renal cell carcinoma tumors, loss of sFRP1, a secreted form of the frizzled receptor that acts as an inhibitor of the Wnt pathway, was identified in 15/15 renal cell carcinoma patients (Gumz et al., 2007) . Our results indicate that SOSTDC1, a BMP antagonist that can also negatively regulate the Wnt pathway (Figure 6 ), is similarly downregulated in kidney cancer. Collectively, these results suggest that upregulation of Wnt signaling via reduction of sFRP1, SOSTDC1 or perhaps other as yet unidentified mechanisms, may make a critical contribution to the development of kidney cancer.
We observed that SOSTDC1 exerts an antiproliferative effect on clear cell renal carcinoma cells (Figure 7) . Similarly, sFRP1 was also reported to negatively affect cell proliferation (Gumz et al., 2007) . Considering that SOSTDC1 is downregulated in virtually all of the 20 cancer specimens we analyzed (Figure 1 ), we speculate that the pervasive decrease in SOSTDC1 in kidney cancers may arise due to the requirement of the malignant cell to overcome this antiproliferative activity of SOSTDC1. Our evidence further suggests that inhibition of both BMP and Wnt pathways may underlie the antiproliferative effect of SOSTDC1. Thus, the BMP antagonist noggin as well as the Wnt antagonist DKK1 also inhibited proliferation in RCC cells (Figure 7 ). The ability of SOSTDC1 to simultaneously antagonize both Wnt and BMP signaling may explain its enhanced antiproliferative activity when compared to noggin and DKK alone (Figure 7) . 
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